Notice to patients

Data Processing Information of patients treated with Dificlir® during 2012—2015

On 8th March 2016, the National Research Ethics Service (NRES) gave Astellas Pharma Europe BV permission to conduct a research to assess the use of Dificlir® (fidaxomicin) in real life conditions. Fidaxomicin is a novel antibiotic agent, approved in Europe for the treatment of a bacterium (*Clostridium difficile*) associated diarrhea in adults.

The study will involve around 512 patient medical records from around 18 hospitals in Europe (Austria, Germany, Spain, United Kingdom) including up to 50 patients from this hospital. The information collected in this study will provide a better understanding of the use of fidaxomicin and will contribute to improve patients' treatment.

Data of patients treated with Dificlir® anywhere from 2012 to 2015 will be processed anonymously, meaning after removal of any information that could identify individual patients. However, in order to first identify patients treated with Dificlir® during that period, patient medical records related to Dificlir® treatments will be reviewed by hospital staff who are working on this study. Reviewers may include hospital staff members who have not been involved in the patients' treatments personally.

If you were admitted at this hospital during 2012—2015, received Dificlir® treatment during your stay and would prefer that your information should not be used for this study, please send an email to the email address below, or ask a member of the hospital's administrative staff to do so on your behalf.

Should you need any more information regarding the study, please do not hesitate to contact the hospital study team at the below email address.

georgina.turner@cht.nhs.uk